Literature DB >> 11912393

Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study.

Antonella Giannantoni1, Savino M Di Stasi, Robert L Stephen, Pierluigi Navarra, Giorgio Scivoletto, Ettore Mearini, Massimo Porena.   

Abstract

PURPOSE: Capsaicin and resiniferatoxin (Sigma Chemical Co., St. Louis, Missouri) administered intravesically are attractive options for treating detrusor hyperreflexia. Because the 2 agents differ in chemical structure and relative potency, possible differences in their clinical and urodynamic effects were investigated in this prospective comparative study.
MATERIALS AND METHODS: A group of 24 spinal cord injured patients with refractory detrusor hyperreflexia were randomly assigned to receive a single dose of 2 mM. capsaicin in 30 ml. ethanol plus 70 ml. 0.9% sodium chloride or 100 nM. resiniferatoxin in 100 ml. 0.9% sodium chloride. Dwell time was 40 minutes with urodynamic monitoring. Urodynamics were performed at baseline before treatment, and after followups of 30 and 60 days. The frequency of daily catheterizations, incontinence episodes and side effects was recorded.
RESULTS: There was no significant urodynamic or clinical improvement in the capsaicin arm at 30 and 60 days of followup. In the resiniferatoxin arm the mean uninhibited detrusor contraction threshold plus or minus standard deviation increased from 176 +/- 54 to 250 +/- 107 ml. at 30 days (p <0.05) and to 275 +/- 98 ml. at 60 days (p <0.01). Mean maximum bladder capacity increased from 196 +/- 75 to 365 +/- 113 ml. at 30 days (p <0.001) and to 357 +/- 101 ml. at 60 days (p <0.001). Daily catheterizations and incontinent episodes were significantly decreased at 30 and 60 days of followup. Autonomic dysreflexia, limb spasms, suprapubic discomfort and hematuria developed in most patients who received capsaicin but in none who received resiniferatoxin.
CONCLUSIONS: Intravesical administration of resiniferatoxin is superior to that of capsaicin in terms of urodynamic results and clinical benefits in spinal cord injured patients and it does not cause the inflammatory side effects associated with capsaicin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11912393

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

Review 1.  [Afferent pathways arising from the lower urinary tract. Physiology, pathophysiology, and clinical implications].

Authors:  A Reitz; A Haferkamp; M Hohenfellner
Journal:  Urologe A       Date:  2005-12       Impact factor: 0.639

Review 2.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

3.  [Intravesical therapy for overactive bladder].

Authors:  J Pannek; U Grigoleit; R Wormland; M Goepel
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

Review 4.  A systematic review of the management of autonomic dysreflexia after spinal cord injury.

Authors:  Andrei Krassioukov; Darren E Warburton; Robert Teasell; Janice J Eng
Journal:  Arch Phys Med Rehabil       Date:  2009-04       Impact factor: 3.966

5.  Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC).

Authors:  Tony Y H Chen; Jacques Corcos; Michel Camel; Yves Ponsot; Le Mai Tu
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-04-08

6.  Mechanisms inducing autonomic dysreflexia during urinary bladder distention in rats with spinal cord injury.

Authors:  T Yoshizawa; K Kadekawa; P Tyagi; S Yoshikawa; R Takahashi; S Takahashi; N Yoshimura
Journal:  Spinal Cord       Date:  2014-12-23       Impact factor: 2.772

7.  Prevention of recurrent autonomic dysreflexia: a survey of current practice.

Authors:  Deborah Caruso; David Gater; Christopher Harnish
Journal:  Clin Auton Res       Date:  2015-08-18       Impact factor: 4.435

Review 8.  Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects.

Authors:  Roderick MacDonald; Manoj Monga; Howard A Fink; Timothy J Wilt
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 9.  Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.

Authors:  Alan D Garely; Lara Burrows
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Overactive bladder: pharmacologic treatments in the neurogenic population.

Authors:  Michael J Kennelly; William B Devoe
Journal:  Rev Urol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.